No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 33 of the 37 quarters in the window, leaving 4 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 31
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Quantum BioPharma Ltd. (QNTM) stock was $3.35 as of Oct 6, 2026, 1:55 PM EDT, up 2.29% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -82.1% · 3-year avg -65.2%/yr · 5-year avg -49.2%/yr
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development.
Biotechnology · Toronto, ON
Next Earnings Date
Nov 6, 2026
31 days away
EPS Estimate
-0.50
Revenue Est.
N/A
Last Quarter Results
EPS
$-4.17
vs Estimate
$-0.68
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1QNTM | $21.40M | $3.35 | +2.29% | -82.13% | -49.16% | N/A | N/A |
| 2MODD | $21.56M | $2.64 | +14.99% | -88.60% | N/A | N/A | vs QNTM |
| 3AYTU | $22.11M | $2.06 | +0.98% | -6.80% | -48.14% | -68.87% | vs QNTM |
| 4NXTC | $20.32M | $5.63 | +11.39% | -13.47% | -44.29% | N/A | vs QNTM |
| 5LONA | $22.54M | $5.71 | +2.42% | +34.59% | -43.13% | N/A | vs QNTM |
| 6RNTX | $22.88M | $0.82 | -0.79% | -30.55% | N/A | N/A | vs QNTM |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 1 analyst
Average Price Target
$12.27
+266.9% upside
Low
$12.27
Current
$3.35
High
$12.27
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.50 | $-0.50 | $-0.50 | 1 |
| Quarter ending Dec 2026 | $-0.75 | $-0.75 | $-0.75 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.85 | $-1.85 | $-1.85 | 1 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $14.96M | $14.96M | $14.96M | 1 |
| FY 2027 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| $26.30M |
| $26.30M |
| $26.30M |
| 1 |
